ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody (original ) (raw )Testing for ROS1 in non-small cell lung cancer: a review with recommendations
büge ÖZ
Virchows Archiv : an international journal of pathology, 2016
View PDFchevron_right
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas
Jean-christophe Sabourin
Lung Cancer, 2014
View PDFchevron_right
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
Felip Garcia Hernandez
View PDFchevron_right
Evaluation of ROS1 expression and rearrangements in a large cohort of early- stage lung cancer
Abdirashid Warsame
View PDFchevron_right
Screening for ROS1 gene rearrangements in non-small cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target
Thắng Trần
Histopathology, 2016
View PDFchevron_right
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
Anh Tuấn Lê
Clinical Cancer Research
View PDFchevron_right
Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series
Fiamma Buttitta
Clinical Lung Cancer, 2014
View PDFchevron_right
Correlation of ROS1 (D4D6) Immunohistochemistry with ROS1 Fluorescence In Situ Hybridization Assay in a Contemporary Cohort of Pulmonary Adenocarcinomas
Sambit Mohanty
South Asian Journal of Cancer
View PDFchevron_right
Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization
Amy Newell
Archives of Pathology & Laboratory Medicine
View PDFchevron_right
Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital
Kashif Khan
Cytopathology, 2021
View PDFchevron_right
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review
Federica Biello
Precision cancer medicine, 2022
View PDFchevron_right
Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples
Anh Thư Lê
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018
View PDFchevron_right
Mouse models for ROS1 -fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency
Yoichi Gondo
Carcinogenesis, 2016
View PDFchevron_right
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Keith Wilner
Journal of Clinical Oncology, 2012
View PDFchevron_right
ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
MOLECULAR PATHOLOGY-A KEY TO PERSONALIZED MEDICINE
Lung India : official organ of Indian Chest Society
View PDFchevron_right
High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer
Wilfried Eberhardt
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016
View PDFchevron_right
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Sacha Rothschild
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
MOLECULAR PATHOLOGY-A KEY TO PERSONALIZED MEDICINE
Lung Cancer: Targets and Therapy
View PDFchevron_right
Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer
Christoph Engelke
Case Reports in Oncology, 2016
View PDFchevron_right
Characteristics of Patients With ROS1+ Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository
Manali Patel
JCO Oncology Practice, 2019
View PDFchevron_right
Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
Brigida Stanzione
International Journal of Molecular Sciences
View PDFchevron_right
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi
Nature Medicine, 2012
View PDFchevron_right
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Keith Wilner
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018
View PDFchevron_right
ROS1 Gene Rearrangement Positive Non-small cell Lung Cancer
Dr.moushumi Suryavanshi
Journal of Case Reports, 2017
View PDFchevron_right
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
Stefan Bagby
Cancers
View PDFchevron_right
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer
Anh Tuấn Lê
PloS one, 2013
View PDFchevron_right
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
Hans-ulrich Schildhaus , Matthias Scheffler
View PDFchevron_right
Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer
Ekaterina Pestova
Lung cancer (Amsterdam, Netherlands), 2017
View PDFchevron_right
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data
Keith Wilner
Future Oncology, 2022
View PDFchevron_right
Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
Layli Prasojo
Molecular and Cellular Biomedical Sciences
View PDFchevron_right
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
Yu Chung Li
The Lancet Oncology, 2019
View PDFchevron_right